{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:07:43Z","timestamp":1787990863728,"version":"build-2784847793"},"reference-count":87,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpedsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Surgery"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jpedsurg.2025.162425","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T19:24:11Z","timestamp":1750447451000},"page":"162425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["What Every Pediatric Surgeon Should Know About Common Systemic Therapies for the Treatment of Renal Tumors in Children and Adolescents"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0026-9774","authenticated-orcid":false,"given":"Alicia D.","family":"Menchaca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shachi","family":"Srivatsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Kieran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fialkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth T.","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo LP.","family":"Romao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Kotagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus M.","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Glick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Cost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-1220","authenticated-orcid":false,"given":"Jennifer H.","family":"Aldrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jpedsurg.2025.162425_bib1","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1002\/ijc.33147","article-title":"Incidence of childhood renal tumours: an international population-based study","volume":"147","author":"Nakata","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib2","series-title":"PDQ cancer information summaries","year":"2002"},{"issue":"6","key":"10.1016\/j.jpedsurg.2025.162425_bib3","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/bjc.1990.432","article-title":"International variations in the incidence of childhood renal tumours","volume":"62","author":"Stiller","year":"1990","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.jpedsurg.2025.162425_bib4","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/cncr.26554","article-title":"A Surveillance, Epidemiology and End Results (SEER) program comparison of adult and pediatric Wilms' tumor","volume":"118","author":"Ali","year":"2012","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.jpedsurg.2025.162425_bib5","article-title":"Pediatric renal tumor epidemiology: global perspectives, progress, and challenges","volume":"70","author":"Libes","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib6","article-title":"Current surgical approaches to pediatric renal tumors","author":"Glick","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"10.1016\/j.jpedsurg.2025.162425_bib7","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2017.77.1931","article-title":"Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the children's oncology group AREN0533 study","volume":"36","author":"Dix","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jpedsurg.2025.162425_bib8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/cncr.35099","article-title":"Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: a report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5","volume":"130","author":"Benedetti","year":"2024","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jpedsurg.2025.162425_bib9","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/his.14632","article-title":"Pathology of Wilms' tumour in International Society of Paediatric Oncology (SIOP) and Children's oncology group (COG) renal tumour studies: similarities and differences","volume":"80","author":"Vujani\u0107","year":"2022","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.jpedsurg.2025.162425_bib10","doi-asserted-by":"crossref","first-page":"475.e1","DOI":"10.1016\/j.jpurol.2020.05.168","article-title":"Incidence, treatment, and outcomes of primary and recurrent Non-Wilms renal tumors in children: report of 109 patients treated at a single institution","volume":"16","author":"Qureshi","year":"2020","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.04.004","article-title":"Vincristine-induced peripheral neuropathy in children with cancer: a systematic review","volume":"114","author":"van de Velde","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib12","unstructured":"Hospira. Vincristine Sulfate. U.S. Food and Drug Administration website. Revised July 2013 October 2024]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/071484s042lbl.pdf."},{"key":"10.1016\/j.jpedsurg.2025.162425_bib13","first-page":"e9","article-title":"Wound healing in patients with cancer","volume":"8","author":"Payne","year":"2008","journal-title":"Eplasty"},{"issue":"2","key":"10.1016\/j.jpedsurg.2025.162425_bib14","first-page":"238","article-title":"Effects of antineoplastic agents on wound healing in mice","volume":"78","author":"Cohen","year":"1975","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162425_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0090-4295(82)90047-4","article-title":"Preoperative chemotherapy for Wilms tumor","volume":"19","author":"Bracken","year":"1982","journal-title":"Urology"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib16","series-title":"Comprehensive Natural Products II","first-page":"109","article-title":"Terrestrial microorganisms \u2013 filamentous bacteria","author":"Singh","year":"2010"},{"issue":"16","key":"10.1016\/j.jpedsurg.2025.162425_bib17","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1073\/pnas.82.16.5328","article-title":"Actinomycin and DNA transcription","volume":"82","author":"Sobell","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jpedsurg.2025.162425_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/(SICI)1096-911X(199710)29:4<245::AID-MPO2>3.0.CO;2-M","article-title":"Veno-occlusive disease of the liver in children treated for Wilms tumor","volume":"29","author":"Bisogno","year":"1997","journal-title":"Med Pediatr Oncol"},{"issue":"3","key":"10.1016\/j.jpedsurg.2025.162425_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0167-8140(94)90427-8","article-title":"Hepatotoxicity in irradiated nephroblastoma patients during postoperative treatment according to SIOP9\/GPOH","volume":"31","author":"Flentje","year":"1994","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib20","series-title":"Cosmogen. Dactinomycin. U.S. Food and drug administration","year":"2018"},{"issue":"5","key":"10.1016\/j.jpedsurg.2025.162425_bib21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/1091581817721675","article-title":"Drug-induced liver injury in children: clinical observations, animal models, and regulatory status","volume":"36","author":"Shi","year":"2017","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib22","series-title":"BC cancer Provincial Pharmacy","year":"2021"},{"issue":"3","key":"10.1016\/j.jpedsurg.2025.162425_bib23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/j.2040-4603.2019.tb00082.x","article-title":"Doxorubicin-induced cardiomyopathy in children","volume":"9","author":"Mancilla","year":"2019","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119527","article-title":"A comprehensive review on time-tested anticancer drug doxorubicin","volume":"278","author":"Sritharan","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib25","series-title":"Doxorubicin, in StatPearls","author":"Johnson-Arbor","year":"2023"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib26","unstructured":"Pfizer. Doxorubicin Hydrochloride. U.S. Food and Drug Administration website. Revised December 2019 [cited Accessed October 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/050467s078,050629s030lbl.pdf."},{"issue":"11","key":"10.1016\/j.jpedsurg.2025.162425_bib27","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib28","unstructured":"Ingenus Pharmaceuticals, LLC.Cyclophosphamide. US Food and Drug Administration. Revised July 2020 Accessed April 2025; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212501s000lbl.pdf."},{"issue":"4","key":"10.1016\/j.jpedsurg.2025.162425_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162425_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0163-7258(90)90049-8","article-title":"Metabolism and pulmonary toxicity of cyclophosphamide","volume":"47","author":"Patel","year":"1990","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jpedsurg.2025.162425_bib31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0014-4800(85)90031-0","article-title":"Pulmonary toxicity of cyclophosphamide: a 1-year study","volume":"42","author":"Morse","year":"1985","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162425_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.jpedsurg.2025.162425_bib33","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1021\/tx060058c","article-title":"Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry","volume":"19","author":"Hah","year":"2006","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162425_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2133\/dmpk.DMPK-12-RV-073","article-title":"Polymorphic transporters and platinum pharmacodynamics","volume":"28","author":"Sprowl","year":"2013","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"4","key":"10.1016\/j.jpedsurg.2025.162425_bib35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1590\/S1984-82502014000400004","article-title":"Carboplatin: molecular mechanisms of action associated with chemoresistance","volume":"50","author":"Fonseca de Sousa","year":"2014","journal-title":"Brazil J Pharma Sci"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib36","series-title":"The Cat","first-page":"768","article-title":"Oncology","author":"Saunders","year":"2012"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib37","series-title":"LiverTox: clinical and research information on drug-induced liver injury [Internet]","year":"2012"},{"issue":"2","key":"10.1016\/j.jpedsurg.2025.162425_bib38","first-page":"71","article-title":"The influence of low flow anaesthesia on renal function in cancer patients previously treated with nephrotoxic chemotherapeutic agents","volume":"44","author":"Wujtewicz","year":"2012","journal-title":"Anaesthesiol Intensive Ther"},{"issue":"2","key":"10.1016\/j.jpedsurg.2025.162425_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5152\/TJAR.2017.72325","article-title":"Comparison of effects of low-flow sevoflurane and low-flow Desflurane anaesthesia on renal functions using Cystatin C","volume":"45","author":"Duymaz","year":"2017","journal-title":"Turk J Anaesthesiol Reanim"},{"issue":"4","key":"10.1016\/j.jpedsurg.2025.162425_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1568011054222364","article-title":"Etoposide, topoisomerase II and cancer","volume":"5","author":"Baldwin","year":"2005","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib41","series-title":"Complications of Urologic surgery","first-page":"117","article-title":"Toxicities of chemotherapy for genitourinary malignancies","author":"Montgomery","year":"2010"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib42","series-title":"Etoposide","year":"2020"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2019.05.033","article-title":"Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study","volume":"118","author":"Daw","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.jpedsurg.2025.162425_bib44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/pbc.20822","article-title":"Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group","volume":"48","author":"Green","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"30","key":"10.1016\/j.jpedsurg.2025.162425_bib45","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.18.01972","article-title":"Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor: a Children's oncology group AREN0532 and AREN0533 study report","volume":"37","author":"Dix","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jpedsurg.2025.162425_bib46","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/SLA.0000000000002356","article-title":"Results of the first prospective multi-institutional treatment study in children with bilateral Wilms tumor (AREN0534): a report from the Children's oncology group","volume":"266","author":"Ehrlich","year":"2017","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162425_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27450","article-title":"Impact of cyclophosphamide and etoposide on outcome of clear cell sarcoma of the kidney treated on the National Wilms Tumor Study-5 (NWTS-5)","volume":"66","author":"Seibel","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib48","series-title":"Encyclopedia of respiratory medicine","first-page":"332","article-title":"TUMORS, MALIGNANT | chemotherapeutic agents","author":"Edelman","year":"2006"},{"issue":"14","key":"10.1016\/j.jpedsurg.2025.162425_bib49","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.01265","article-title":"Activity of vincristine and irinotecan in diffuse anaplastic Wilms tumor and therapy outcomes of stage II to IV disease: results of the Children's oncology group AREN0321 study","volume":"38","author":"Daw","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jpedsurg.2025.162425_bib50","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1007\/s10151-011-0755-8","article-title":"Intraperitoneally administered irinotecan with 5-fluorouracil impair wound healing of colonic anastomoses in a rat model: an experimental study","volume":"15","author":"Pramateftakis","year":"2011","journal-title":"Tech Coloproctol"},{"issue":"10","key":"10.1016\/j.jpedsurg.2025.162425_bib51","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"10.1016\/j.jpedsurg.2025.162425_bib53","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162425_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1385\/MO:19:1:25","article-title":"Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma","volume":"19","author":"Puls","year":"2002","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.jpedsurg.2025.162425_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.jpedsurg.2025.162425_bib56","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 expression in nonclear-cell renal cell carcinoma","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162425_bib57","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41598-017-02005-7","article-title":"PD-L1 expression in Xp11.2 translocation renal cell carcinoma: indicator of tumor aggressiveness","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jpedsurg.2025.162425_bib58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.jpedsurg.2025.162425_bib59","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jpedsurg.2025.162425_bib60","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jpedsurg.2025.162425_bib61","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162425_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"24","key":"10.1016\/j.jpedsurg.2025.162425_bib63","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jpedsurg.2025.162425_bib64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/11591240-000000000-00000","article-title":"Axitinib for the management of metastatic renal cell carcinoma","volume":"11","author":"Escudier","year":"2011","journal-title":"Drugs R&D"},{"issue":"9807","key":"10.1016\/j.jpedsurg.2025.162425_bib65","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jpedsurg.2025.162425_bib66","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jpedsurg.2025.162425_bib67","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib68","series-title":"Inlyta (axitinib) + pembrolizumab therapy management guide","author":"Oncology","year":"2024"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162425_bib69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00204-024-03874-4","article-title":"Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies","volume":"99","author":"Du","year":"2025","journal-title":"Arch Toxicol"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162425_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96467-5","article-title":"Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data","volume":"11","author":"Makunts","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jpedsurg.2025.162425_bib71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/KCA-170016","article-title":"Surgical complications of presurgical systemic therapy for renal cell carcinoma: a systematic review","volume":"1","author":"McCormick","year":"2017","journal-title":"Kidney Cancer"},{"issue":"4","key":"10.1016\/j.jpedsurg.2025.162425_bib72","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/2211-5463.13579","article-title":"Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1","volume":"13","author":"Hong","year":"2023","journal-title":"FEBS Open Bio"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162425_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48774-2","article-title":"Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors","volume":"13","author":"Vejmelkova","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib74","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.18871","article-title":"Safety profile of EZH2 inhibitors for cancer: a systematic review and meta-analysis","volume":"13","author":"Zhao","year":"2025","journal-title":"PeerJ"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib75","series-title":"xPharm: the comprehensive Pharmacology Reference","first-page":"1","article-title":"Everolimus","author":"Beljanski","year":"2008"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib76","series-title":"Cellular Transplantation","first-page":"13","article-title":"Current immunosuppressive drugs and clinical use","author":"Pollinger","year":"2007"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/CE.S98687","article-title":"Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy","volume":"11","author":"Buti","year":"2016","journal-title":"Core Evid"},{"issue":"8","key":"10.1016\/j.jpedsurg.2025.162425_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27766","article-title":"Treatment of advanced pediatric renal cell carcinoma","volume":"66","author":"Ambalavanan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.jpedsurg.2025.162425_bib79","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/1535-7163.MCT-10-0905","article-title":"Pushing the envelope in the mTOR pathway: the second generation of inhibitors","volume":"10","author":"Vilar","year":"2011","journal-title":"Mol Cancer Therapeut"},{"issue":"3","key":"10.1016\/j.jpedsurg.2025.162425_bib80","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib81","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6255339","article-title":"Mammalian target of rapamycin inhibitors and wound healing complications in kidney transplantation: old myths and new realities","volume":"2022","author":"Mabood Khalil","year":"2022","journal-title":"J Transplant"},{"issue":"3","key":"10.1016\/j.jpedsurg.2025.162425_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32030154","article-title":"Perioperative drug management of systemic therapies in breast cancer: a literature review and treatment recommendations","volume":"32","author":"Galuia","year":"2025","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.jpedsurg.2025.162425_bib83","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.TP.0000072016.13090.4E","article-title":"Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study","volume":"76","author":"Troppmann","year":"2003","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.jpedsurg.2025.162425_bib84","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","article-title":"Bevacizumab","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.jpedsurg.2025.162425_bib86","first-page":"3953","article-title":"Bevacizumab in pediatric patients: how safe is it?","volume":"31","author":"de Pasquale","year":"2011","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.jpedsurg.2025.162425_bib87","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdm510","article-title":"Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors","volume":"19","author":"Benesch","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jpedsurg.2025.162425_bib88","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jpedsurg.2025.162425_bib89","series-title":"Avastin (bevacizumab)","year":"2025"}],"container-title":["Journal of Pediatric Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022346825002702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022346825002702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:56:25Z","timestamp":1757627785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022346825002702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":87,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0022346825002702"],"URL":"https:\/\/doi.org\/10.1016\/j.jpedsurg.2025.162425","relation":{},"ISSN":["0022-3468"],"issn-type":[{"value":"0022-3468","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Every Pediatric Surgeon Should Know About Common Systemic Therapies for the Treatment of Renal Tumors in Children and Adolescents","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpedsurg.2025.162425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"162425"}}